C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer
Cora N. Sternberg,Peter Whelan,J. W. Hetherington,B. Paluchowska,P.H.Th.J. Slee,K. Vekemans,P. van Erps,Christine Theodore,O. Koriakine,T. Oliver,D. Lebwohl,M. Debois,A Zurlo,L. Collette +13 more
TL;DR: This randomized comparison of a combination of satraplatin and prednisone versusprednisone alone supports the antitumor activity of the combination.
Journal ArticleDOI
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.
Evan Y. Yu,George Wilding,Edwin M. Posadas,Mitchell E. Gross,Stéphane Culine,Christophe Massard,Michael J. Morris,Gary R. Hudes,Fabio Calabrò,Shinta Cheng,Geralyn C. Trudel,Prashni Paliwal,Cora N. Sternberg +12 more
TL;DR: Encouraging evidence is provided of dasatinib activity in bone and reasonable tolerability in chemotherapy-naive patients with metastatic CRPC and treatment-related adverse events were moderate.
Journal ArticleDOI
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology.
Jean Pierre Droz,Lodovico Balducci,Michel Bolla,Mark Emberton,John M. Fitzpatrick,Steven Joniau,Michael W. Kattan,Silvio Monfardini,Judd W. Moul,Arash Naeim,Hendrik Van Poppel,Fred Saad,Cora N. Sternberg +12 more
TL;DR: The consensus of the SIOG Prostate Cancer Task Force is that older men with prostate cancer should be managed according to their individual health status, which is mainly driven by the severity of associated comorbid conditions, and not according to chronological age.
Journal ArticleDOI
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion.
Howard I. Scher,Alan Yagoda,Harry W. Herr,Cora N. Sternberg,George J. Bosl,Michael J. Morse,Pramod C. Sogani,Robin C. Watson,D. David Dershaw,Victor E. Reuter,Nancy L. Geller,Phyllis Hollander,E. Darracott Vaughan,Willet F. Whitmore,William R. Fair +14 more
TL;DR: While this active regimen can clinically (T) and pathologically (P) induce downstaging in a significant number of patients with primary bladder tumors, this pilot study has raised serious questions concerning the design of future nonrandomized and randomized neoadjuvant studies.
Journal ArticleDOI
Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
Tim Eisen,Cora N. Sternberg,Caroline Robert,Peter F.A. Mulders,Lynda Pyle,Stephan Zbinden,Hassan Izzedine,Bernard Escudier +7 more
TL;DR: There is a need for further systematic investigation of management strategies for AEs related to targeted therapies for RCC, because the evidence for the suggested management strategies is largely anecdotal.